|| Checking for direct PDF access through Ovid
The objective of this study was to determine the gadolinium (Gd) concentration remaining in human bone tissue after administration of standard clinical doses of 2 Gd-based contrast agents: ProHance and Omniscan.After administration of 0.1 mmol/kg of Gd chelate to patients undergoing hip replacement surgery, bone specimens were collected and analyzed, and compared with an age-matched control population without a history of Gd chelate administration. Bone specimens were collected fresh, refrigerated, and subsequently frozen. After grinding and freeze-drying, tissue digestion was performed using Teflon bombs and concentrated nitric acid. A method for analysis of Gd in bone specimens was developed and validated using inductively coupled plasma mass spectroscopy (ICP-MS).Results were compared with a previous study using a different technique for analysis of the same tissue specimens. Tissue retention was 1.77 ± 0.704 μg Gd/g bone (n = 9) for Omniscan and 0.477 ± 0.271 μg Gd/g bone (n = 10) for ProHance measured by ICP-MS. These findings confirmed results from the previous ICP-AES study.Omniscan (Gd[DTPA-BMA]) left approximately 4 times (previous study 2.5 times) more Gd behind in bone than did ProHance (Gd[HP-DO3A]).